Despite warnings about the dangers of type 2 diabetes drug Ozempic, its makers Novo Nordisk, an esteemed member of Big Pharma, continues to profit.

Recently, the firm became Europe’s most valuable company with a market cap over $350 billion as Hollywood stars and celebrities praised its products.

However, the question remains: Can you get any shadier than profiting from a potentially dangerous drug, especially with Novo Nordisk’s ties to controversial firms?